Skip to main content
European Commission logo print header

Perinatal Life Support System: Integration of Enabling Technologies for Clinical Translation

Descrizione del progetto

Un sistema di supporto vitale per neonati estremamente pretermine

Una grande percentuale dei neonati estremamente pretermine che sopravvivono (< 28 settimane) affronta disabilità permanenti correlate a problemi cardiovascolari, neurologici, respiratori e metabolici. L’approccio attuale coinvolge l’avvio delle funzioni organiche ma i polmoni e l’intestino negli organi immaturi non sono adatti per tali interventi. Il consorzio, finanziato dall’UE, progetterà e svilupperà un sistema completamente nuovo di assistenza per questi neonati, ricreando ex vivo condizioni fisiologiche cardiorespiratorie fetali innate. Il sistema includerà una placenta artificiale con scambio di ossigeno e sostanze nutritive, costante monitoraggio non invasivo dei parametri fetali, modello anatomico fetale per la simulazione del neonato e corrispondente modellizzazione computazionale. Un team interdisciplinare di partner accademici e industriali hanno unito le loro forze per dimostrare la funzionalità del sistema in una prova di principio.

Obiettivo

Every year, 800.000 babies are born extremely preterm (EP; <28 weeks of age) worldwide. A large proportion of survivors from this group of smallest infants face lifelong disabilities, including breathing, cardiac, neurological and metabolic problems. Current treatment requires the preterm initiation of body functions for which the respective organs are not prepared. This affects primarily the lungs which need to provide gas-exchange under air (i.e. oxygen-based mechanical ventilation), and the gut, which is needed for energy and nutrition. This approach causes major therapy-related morbidity such as bronchopulmonary dysplasia, necrotizing enterocolitis and germinal matrix bleeding. The Perinatal Life Support (PLS) consortium envisions a medical device that can support the safe development of EP infants outside the womb by preserving the innate fetal cardiorespiratory physiology ex vivo, with the following enabling technologies:
1. A liquid-based environment with oxygen and nutrient exchange using an ´artificial placenta´;
2. Continuous and non-invasive monitoring of fetal parameters such as heart rate and oxygenation;
3. Computational models for fast and objective clinical decision support based on physiological data input;
4. A fetal manikin that can accurately simulate EP infants in an intensive care setting.
The PLS project will be carried out by an interdisciplinary group of academia and industry with experience in modelling, monitoring, engineering, obstetrics and neonatology. The technology underlying PLS is applicable to conditions where ex vivo life support is required e.g. organ perfusion, regeneration and transplantation. The integrated system will allow major progress towards translation for an urgent medical need, where new solutions are lacking as preclinical models are inadequate and clinical trials not feasible. Innovative simulation technology will enable technical validation of PLS, with demonstration of functionality in a final Proof-of-Principle.

Invito a presentare proposte

H2020-FETOPEN-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-FETOPEN-2018-2019-2020-01

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

TECHNISCHE UNIVERSITEIT EINDHOVEN
Contribution nette de l'UE
€ 792 500,00
Indirizzo
GROENE LOPER 3
5612 AE Eindhoven
Paesi Bassi

Mostra sulla mappa

Regione
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 792 500,00

Partecipanti (4)